OA12024A - Polymorphic salt. - Google Patents

Polymorphic salt. Download PDF

Info

Publication number: OA12024A
Authority: OA; OAPI
Prior art keywords: compound; polymorph; suitable solvent; daims; tetrahydrofuran
Prior art date: 1999-09-28

Application number

OA1200200077A

Other languages

English (en)

Inventor

Arthur Bentley

Simon Arnold Howard-Field

Ronald James Ogilvie

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-28

Filing date

2000-09-14

Publication date

2006-04-19

2000-09-14 Application filed by Pfizer filed Critical Pfizer

2006-04-19 Publication of OA12024A publication Critical patent/OA12024A/en

Links

150000003839 salts Chemical class 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 28
238000000034 method Methods 0.000 claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 7
238000011282 treatment Methods 0.000 claims abstract description 7
239000000556 agonist Substances 0.000 claims abstract description 5
230000005855 radiation Effects 0.000 claims abstract description 4
208000019695 Migraine disease Diseases 0.000 claims abstract description 3
206010027599 migraine Diseases 0.000 claims abstract description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract 3
229910052802 copper Inorganic materials 0.000 claims abstract 3
239000010949 copper Substances 0.000 claims abstract 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 23
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
239000002904 solvent Substances 0.000 claims description 13
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
238000010992 reflux Methods 0.000 claims description 9
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
239000002002 slurry Substances 0.000 claims description 5
238000010521 absorption reaction Methods 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 4
238000002329 infrared spectrum Methods 0.000 claims description 4
206010019233 Headaches Diseases 0.000 claims description 3
239000006185 dispersion Substances 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 2
208000006561 Cluster Headache Diseases 0.000 claims description 2
206010013654 Drug abuse Diseases 0.000 claims description 2
208000030814 Eating disease Diseases 0.000 claims description 2
208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
208000008589 Obesity Diseases 0.000 claims description 2
206010047700 Vomiting Diseases 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
208000018912 cluster headache syndrome Diseases 0.000 claims description 2
235000014632 disordered eating Nutrition 0.000 claims description 2
231100000869 headache Toxicity 0.000 claims description 2
238000010438 heat treatment Methods 0.000 claims description 2
238000010899 nucleation Methods 0.000 claims description 2
235000020824 obesity Nutrition 0.000 claims description 2
208000011117 substance-related disease Diseases 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims 1
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
102000035038 5-HT1 receptors Human genes 0.000 abstract description 2
108091005478 5-HT1 receptors Proteins 0.000 abstract description 2
239000003814 drug Substances 0.000 abstract description 2
239000000243 solution Substances 0.000 description 19
239000003826 tablet Substances 0.000 description 14
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
239000002775 capsule Substances 0.000 description 7
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000008101 lactose Substances 0.000 description 6
239000000843 powder Substances 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
238000007906 compression Methods 0.000 description 5
230000006835 compression Effects 0.000 description 5
229920002785 Croscarmellose sodium Polymers 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229960001681 croscarmellose sodium Drugs 0.000 description 4
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
-1 for example Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
229940032147 starch Drugs 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000005406 washing Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
235000019759 Maize starch Nutrition 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000002844 melting Methods 0.000 description 3
239000002674 ointment Substances 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
238000012958 reprocessing Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000001117 sulphuric acid Substances 0.000 description 3
235000011149 sulphuric acid Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
230000008018 melting Effects 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000001144 powder X-ray diffraction data Methods 0.000 description 2
239000003380 propellant Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
229940124433 antimigraine drug Drugs 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
229940116224 behenate Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
238000007707 calorimetry Methods 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940081733 cetearyl alcohol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
238000010410 dusting Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000000646 scanning calorimetry Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000004441 surface measurement Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200200077A 1999-09-28 2000-09-14 Polymorphic salt. OA12024A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9922963.5A GB9922963D0 (en)	1999-09-28	1999-09-28	Polymorphic salt

Publications (1)

Publication Number	Publication Date
OA12024A true OA12024A (en)	2006-04-19

Family

ID=10861767

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200077A OA12024A (en)	1999-09-28	2000-09-14	Polymorphic salt.

Country Status (50)

Country	Link
US (1)	US6369094B1 (xx)
EP (1)	EP1233960B1 (xx)
JP (1)	JP3795395B2 (xx)
KR (1)	KR100479897B1 (xx)
CN (1)	CN1155594C (xx)
AP (1)	AP2004A (xx)
AR (1)	AR025779A1 (xx)
AT (1)	ATE246185T1 (xx)
AU (1)	AU779580B2 (xx)
BG (1)	BG65161B1 (xx)
BR (1)	BR0014272A (xx)
CA (1)	CA2379572C (xx)
CO (1)	CO5180567A1 (xx)
CR (1)	CR6561A (xx)
CU (1)	CU23200A3 (xx)
CZ (1)	CZ2002971A3 (xx)
DE (1)	DE60004262T2 (xx)
DK (1)	DK1233960T3 (xx)
DZ (1)	DZ3254A1 (xx)
EA (1)	EA004510B1 (xx)
EE (1)	EE200200171A (xx)
EG (1)	EG24143A (xx)
ES (1)	ES2200911T3 (xx)
GB (1)	GB9922963D0 (xx)
GE (1)	GEP20043365B (xx)
GT (1)	GT200000159A (xx)
HK (1)	HK1048628B (xx)
HR (1)	HRP20020270B1 (xx)
HU (1)	HUP0202821A3 (xx)
IL (1)	IL147154A (xx)
IS (1)	IS2162B (xx)
MA (1)	MA26821A1 (xx)
MX (1)	MXPA02003311A (xx)
MY (1)	MY121170A (xx)
NO (1)	NO321936B1 (xx)
NZ (1)	NZ516093A (xx)
OA (1)	OA12024A (xx)
PA (1)	PA8498901A1 (xx)
PE (1)	PE20010662A1 (xx)
PL (1)	PL354960A1 (xx)
PT (1)	PT1233960E (xx)
SI (1)	SI1233960T1 (xx)
SK (1)	SK3982002A3 (xx)
TN (1)	TNSN00187A1 (xx)
TR (1)	TR200200804T2 (xx)
TW (1)	TWI265926B (xx)
UA (1)	UA72272C2 (xx)
WO (1)	WO2001023377A2 (xx)
YU (1)	YU2602A (xx)
ZA (1)	ZA200202406B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7214711B2 (en) *	1998-12-23	2007-05-08	Neurotherapeutics Pharma Llc	Method of treating migraine headache without aura
US8008283B2 (en) *	1998-12-23	2011-08-30	Neurotherapeutics Pharma, Inc.	Methods and compositions for the treatment of neuropsychiatric disorders
US8722668B2 (en) *	1998-12-23	2014-05-13	Daryl W. Hochman	Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US20060025387A1 (en) *	1998-12-23	2006-02-02	Cytoscan Sciences Llc	Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
GB0018968D0 (en) *	2000-08-02	2000-09-20	Pfizer Ltd	Particulate composition
US7132549B2 (en)	2003-05-30	2006-11-07	Pfizer Inc.	Process
GB0312478D0 (en) *	2003-05-30	2003-07-09	Pfizer Ltd	Improved process
EP3165220B2 (en) *	2004-12-03	2024-11-13	Merck Sharp & Dohme LLC	Pharmaceutical composition containing an anti-nucleating agent
EP1951702A2 (en) *	2005-10-17	2008-08-06	NeuroTherapeutics Pharma, Inc.	Diuretic-like compound analogs useful for regulation of central nervous system disorders
KR100814109B1 (ko) *	2006-01-09	2008-03-14	한국생명공학연구원	로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TWI394753B (zh) *	2006-03-17	2013-05-01	Otsuka Pharma Co Ltd	新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
WO2010116386A2 (en) *	2009-04-08	2010-10-14	Biophore India Pharmaceuticals Pvt. Ltd.	Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
PL2493312T3 (pl)	2009-10-26	2022-01-03	Merck Sharp & Dohme Corp.	Kompozycje farmaceutyczne w postaci ciała stałego zawierające inhibitor integrazy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5559129A (en)	1990-10-15	1996-09-24	Pfizer Inc	Indole derivatives
JP2575272B2 (ja) *	1990-10-15	1997-01-22	フアイザー・インコーポレイテツド	インドール誘導体
US5559246A (en)	1990-10-15	1996-09-24	Pfizer Inc.	Indole derivatives
US5607951A (en)	1990-10-15	1997-03-04	Pfizer Inc	Indole derivatives
US5578612A (en)	1990-10-15	1996-11-26	Pfizer Inc.	Indole derivatives
US5545644A (en)	1990-10-15	1996-08-13	Pfizer Inc.	Indole derivatives
GB9417310D0 (en) *	1994-08-27	1994-10-19	Pfizer Ltd	Therapeutic agents
US5998462A (en) *	1996-12-16	1999-12-07	Allelix Biopharmaceuticals Inc.	5-alkyl indole compounds
ID24528A (id) *	1997-07-03	2000-07-20	Pfizer	Komposisi-komposisi obat farmasi yang mengandung eletriptan hemisulfat dan kafein

1999
- 1999-09-28 GB GBGB9922963.5A patent/GB9922963D0/en not_active Ceased
2000
- 2000-07-25 TW TW089114850A patent/TWI265926B/zh not_active IP Right Cessation
- 2000-07-28 PA PA20008498901A patent/PA8498901A1/es unknown
- 2000-08-10 CO CO00059853A patent/CO5180567A1/es not_active Application Discontinuation
- 2000-09-14 AT AT00954864T patent/ATE246185T1/de not_active IP Right Cessation
- 2000-09-14 PT PT00954864T patent/PT1233960E/pt unknown
- 2000-09-14 DK DK00954864T patent/DK1233960T3/da active
- 2000-09-14 HU HU0202821A patent/HUP0202821A3/hu unknown
- 2000-09-14 BR BR0014272-7A patent/BR0014272A/pt not_active Application Discontinuation
- 2000-09-14 JP JP2001526529A patent/JP3795395B2/ja not_active Expired - Fee Related
- 2000-09-14 PL PL00354960A patent/PL354960A1/xx not_active IP Right Cessation
- 2000-09-14 CZ CZ2002971A patent/CZ2002971A3/cs unknown
- 2000-09-14 KR KR10-2002-7003963A patent/KR100479897B1/ko not_active IP Right Cessation
- 2000-09-14 ES ES00954864T patent/ES2200911T3/es not_active Expired - Lifetime
- 2000-09-14 UA UA2002032432A patent/UA72272C2/uk unknown
- 2000-09-14 GE GE4699A patent/GEP20043365B/en unknown
- 2000-09-14 TR TR2002/00804T patent/TR200200804T2/xx unknown
- 2000-09-14 OA OA1200200077A patent/OA12024A/en unknown
- 2000-09-14 SI SI200030165T patent/SI1233960T1/xx unknown
- 2000-09-14 EA EA200200302A patent/EA004510B1/ru not_active IP Right Cessation
- 2000-09-14 YU YU2602A patent/YU2602A/sh unknown
- 2000-09-14 NZ NZ516093A patent/NZ516093A/xx unknown
- 2000-09-14 WO PCT/IB2000/001305 patent/WO2001023377A2/en active IP Right Grant
- 2000-09-14 SK SK398-2002A patent/SK3982002A3/sk unknown
- 2000-09-14 CA CA002379572A patent/CA2379572C/en not_active Expired - Fee Related
- 2000-09-14 DZ DZ003254A patent/DZ3254A1/fr active
- 2000-09-14 IL IL14715400A patent/IL147154A/xx not_active IP Right Cessation
- 2000-09-14 EP EP00954864A patent/EP1233960B1/en not_active Expired - Lifetime
- 2000-09-14 DE DE60004262T patent/DE60004262T2/de not_active Expired - Lifetime
- 2000-09-14 MX MXPA02003311A patent/MXPA02003311A/es active IP Right Grant
- 2000-09-14 AP APAP/P/2002/002457A patent/AP2004A/en active
- 2000-09-14 AU AU67213/00A patent/AU779580B2/en not_active Ceased
- 2000-09-14 EE EEP200200171A patent/EE200200171A/xx unknown
- 2000-09-14 CN CNB00810798XA patent/CN1155594C/zh not_active Expired - Fee Related
- 2000-09-19 US US09/664,946 patent/US6369094B1/en not_active Expired - Fee Related
- 2000-09-25 EG EG20001216A patent/EG24143A/xx active
- 2000-09-26 MY MYPI20004476A patent/MY121170A/en unknown
- 2000-09-26 PE PE2000001010A patent/PE20010662A1/es not_active Application Discontinuation
- 2000-09-26 GT GT200000159A patent/GT200000159A/es unknown
- 2000-09-26 AR ARP000105032A patent/AR025779A1/es active IP Right Grant
- 2000-09-27 TN TNTNSN00187A patent/TNSN00187A1/fr unknown
2001
- 2001-12-10 CU CU20010293A patent/CU23200A3/es not_active IP Right Cessation
- 2001-12-19 BG BG106240A patent/BG65161B1/bg unknown
2002
- 2002-01-08 IS IS6223A patent/IS2162B/is unknown
- 2002-01-24 CR CR6561A patent/CR6561A/es not_active Application Discontinuation
- 2002-03-15 MA MA26556A patent/MA26821A1/fr unknown
- 2002-03-26 NO NO20021525A patent/NO321936B1/no not_active IP Right Cessation
- 2002-03-26 ZA ZA200202406A patent/ZA200202406B/en unknown
- 2002-03-28 HR HR20020270A patent/HRP20020270B1/xx not_active IP Right Cessation
2003
- 2003-01-07 HK HK03100144.2A patent/HK1048628B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR0014272A (pt)	2002-05-21
EA200200302A1 (ru)	2002-10-31
ES2200911T3 (es)	2004-03-16
BG65161B1 (bg)	2007-04-30
ATE246185T1 (de)	2003-08-15
JP3795395B2 (ja)	2006-07-12
IS6223A (is)	2002-01-08
MXPA02003311A (es)	2002-10-04
HUP0202821A2 (hu)	2003-01-28
NZ516093A (en)	2005-01-28
IS2162B (is)	2006-11-15
KR20020032627A (ko)	2002-05-03
WO2001023377A3 (en)	2002-03-07
EG24143A (en)	2008-08-06
HK1048628B (zh)	2004-10-21
CA2379572C (en)	2006-11-14
HRP20020270B1 (en)	2004-04-30
IL147154A0 (en)	2002-08-14
CA2379572A1 (en)	2001-04-05
CN1364166A (zh)	2002-08-14
AP2004A (en)	2009-06-10
EP1233960A2 (en)	2002-08-28
NO321936B1 (no)	2006-07-24
TNSN00187A1 (fr)	2005-11-10
CR6561A (es)	2005-04-04
SI1233960T1 (en)	2003-12-31
CZ2002971A3 (cs)	2003-04-16
GB9922963D0 (en)	1999-12-01
NO20021525D0 (no)	2002-03-26
AU779580B2 (en)	2005-01-27
UA72272C2 (uk)	2005-02-15
DE60004262D1 (de)	2003-09-04
PE20010662A1 (es)	2001-06-23
WO2001023377A2 (en)	2001-04-05
EE200200171A (et)	2003-06-16
EA004510B1 (ru)	2004-04-29
WO2001023377A9 (en)	2002-03-28
HRP20020270A2 (en)	2003-06-30
MA26821A1 (fr)	2004-12-20
IL147154A (en)	2005-11-20
JP2003510318A (ja)	2003-03-18
CO5180567A1 (es)	2002-07-30
NO20021525L (no)	2002-03-26
DE60004262T2 (de)	2004-01-22
CU23200A3 (es)	2007-04-06
BG106240A (en)	2002-07-31
AR025779A1 (es)	2002-12-11
TR200200804T2 (tr)	2002-07-22
SK3982002A3 (en)	2003-05-02
TWI265926B (en)	2006-11-11
PT1233960E (pt)	2003-11-28
CN1155594C (zh)	2004-06-30
GEP20043365B (en)	2004-05-10
ZA200202406B (en)	2003-05-28
DK1233960T3 (da)	2003-10-27
AU6721300A (en)	2001-04-30
EP1233960B1 (en)	2003-07-30
DZ3254A1 (fr)	2001-04-05
YU2602A (sh)	2004-11-25
HK1048628A1 (en)	2003-04-11
PL354960A1 (en)	2004-03-22
PA8498901A1 (es)	2004-02-07
KR100479897B1 (ko)	2005-03-31
US6369094B1 (en)	2002-04-09
GT200000159A (es)	2002-03-20
AP2002002457A0 (en)	2002-06-30
HUP0202821A3 (en)	2003-12-29
MY121170A (en)	2005-12-30

Publication	Publication Date	Title
US6380226B1 (en)	2002-04-30	Salts of an anti-migraine indole derivatives
JP5043825B2 (ja)	2012-10-10	Ｄｐｐ−ｉｖ阻害剤の新規な塩及び多形
OA12024A (en)	2006-04-19	Polymorphic salt.
TW200838512A (en)	2008-10-01	Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
CA2352392C (en)	2006-01-24	Eletriptan hydrobromide monohydrate
WO1997005129A1 (fr)	1997-02-13	(r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridine-carboxamide, son procede d'obtention et medicament le contenant
MXPA04010845A (es)	2005-01-25	Formas cristalinas novedosas de ondansetron, procesos para su preparacion, composiciones farmaceuticas que contienen las formas novedosas y metodos para tratar las nauseas utilizando las mismas.
AU2009292476A1 (en)	2010-03-18	Novel crystal forms of 4-(2-aminopyridin-4-yl)-3-(4fluoro- phenyl)-1-(1,4,5,6-tetrahydro-6-oxopyridazin-3-yl)-1H-pyra-zole methanesulfonate and process for production of same
US20050131045A1 (en)	2005-06-16	Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
JPH09100276A (ja)	1997-04-15	（ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体及びそれを含有する医薬
KR20070030962A (ko)	2007-03-16	신규의 온단세트론 결정 형태의 제조 방법